New Delhi, Jul 15 (Prensa Latina) Biocon, India’s largest biopharmaceutical company, highlighted on Wednesday the production of the drug Itolizumab, developed by the Cuban Center of Molecular Immunology to treat seriously ill Covid-19 patients.
Biocon recently obtained approval from the Drugs Controller General of India to produce Itolizumab (ALZUMAb), which is used to treat plaque psoriasis, for emergency use in India in moderate to severe Covid-19 patients.
Itolizumab is a molecule that was developed by the Havana-based Center of Molecular Immunology to treat lymphomas and leukemia.
National Award of the Cuban Academy of Sciences in 2014, the humanized monoclonal antibody is part of the protocol established in the country to treat Covid-19 patients.
With this drug, 60% of severely and critically ill patients regain lung function and survive the disease.
Powered by Plenglish